Brain Metastases

ABSTRACT

Approximately 10% of patients with cancer develop brain metastases. Although usually appearing late in the course of the disease, the brain metastasis may be present before the primary cancer has been identified and may present as a single lesion or as multiple lesions. The diagnostic and therapeutic approach depends on the number and location of brain lesions and the stage of the cancer. Patients with brain metastases are rarely cured. However, appropriate treatment can improve both the quality and duration of the patient's life. Treatment must be directed not only at the brain metastasis (definitive care), but also at a multitude of other symptoms that plague patients with cancer and brain metastases (supportive care). Judicious selection of pharmacological agents can effectively treat many serious symptoms in patients with brain metastases, but injudicious selection of pharmacological agents, through side effects, may make the patients' quality of life worse. This article reviews some aspects of both definitive and supportive care with particular attention to the side effects of some commonly used pharmacological agents.

Brain metastasis - supportive care - corticosteroids - seizures - venous thromboembolism

REFERENCES

• 1 Posner J B, Chernik N L. Intracranial metastases from systemic cancer.  Adv Neurol. 1978;  19 579-592
• 2 Cairncross J G, Kim J-H, Posner J B. Radiation therapy of brain metastases.  Ann Neurol. 1980;  7 529-541
• 3 Katz A, Zalewski P. Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib.  Br J Cancer. 2003;  89(S2) S15-S18
• 4 Posner J B. Neurologic Complications of Cancer. Philadelphia; F.A. Davis 1995
• 5 Lassman A B, DeAngelis L M. Brain metastases.  Neurol Clin. 2003;  21 1-23
• 6 Schiff D, Wen P Y. Cancer Neurology in Clinical Practice. 1st ed. Totowa, NJ; Humana Press Inc. 2002
• 7 Wen P Y, Marks P W. Medical management of patients with brain tumors.  Curr Opin Oncol. 2002;  14 299-307
• 8 Chang E L, Hassenbusch III S J, Shiu A S et al.. The role of tumor size in the radiosurgical management of patients with ambiguous brain metastases.  Neurosurgery. 2003;  53 272-280
• 9 Bindal A K, Bindal R K, Hess K R et al.. Surgery versus radiosurgery in the treatment of brain metastasis.  J Neurosurg. 1996;  84 748-754
• 10 Brown P D, Brown C A, Pollock B E, Gorman D A, Foote R L. Stereotactic radiosurgery for patients with “radioresistant” brain metastases.  Neurosurgery. 2002;  51 656-665
• 11 Pavlidis N, Briasoulis E, Hainsworth J et al.. Diagnostic and therapeutic management of cancer of an unknown primary.  Eur J Cancer. 2003;  39 1990-2005
• 12 Shu H-KG, Sneed P K, Shiau C-Y et al.. Factors influencing survival after gamma knife radiosurgery for patients with single and multiple brain metastases.  Cancer J Sci Am. 1996;  2 335-342
• 13 Van de Pol M, Van Aalst V C, Wilmink J T et al.. Brain metastases from an unknown primary tumour: which diagnostic procedures are indicated?.  J Neurol Neurosurg Psychiatry. 1996;  61 321-323
• 14 Sneed P K, Lamborn K R, Forstner J M et al.. Radiosurgery for brain metastases: is whole brain radiotherapy necessary?.  Int J Radiat Oncol Biol Phys. 1999;  43 549-558
• 15 Abrey L E, Christodoulou C. Temozolomide for treating brain metastases.  Semin Oncol. 2001;  28 34-42
• 16 Cortes J, Rodriguez J, Aramendia J M et al.. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer.  Oncology. 2003;  64 28-35
• 17 Corcoran M E. Polypharmacy in the older patient with cancer.  Cancer Control. 1997;  4 419-428
• 18 Lu S, Ahn D, Johnson G et al.. Peritumoral diffusion tensor imaging of high-grade gliomas and metastatic brain tumors.  AJNR Am J Neuroradiol. 2003;  24 937-941
• 19 Machein M R, Plate K H. VEGF in brain tumors.  J Neurooncol. 2000;  50 109-120
• 20 Lieberman A, LeBrun Y, Glass P et al.. Use of high-dose corticosteroids in patients with inoperable brain tumors.  J Neurol Neurosurg Psychiatry. 1977;  40 678-682
• 21 Wooldridge J E, Anderson C M, Perry M C. Corticosteroids in advanced cancer.  Oncology (Huntingt). 2001;  15 225-234
• 22 Mertens W C, Higby D J, Brown D et al.. Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines.  J Clin Oncol. 2003;  21 1373-1378
• 23 Heiss J D, Papavassiliou E, Merrill M J et al.. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats-involvement of the glucocorticoid receptor and vascular permeability factor.  J Clin Invest. 1996;  98 1400-1408
• 24 Batchelor T T, Taylor L P, Thaler H T et al.. Steroid myopathy in cancer patients.  Neurology. 1997;  48 1234-1238
• 25 Sieb J P, Gillessen T. Iatrogenic and toxic myopathies.  Muscle Nerve. 2003;  27 142-156
• 26 DiGiovanni S, Molon A, Broccolini A et al.. Constitutive activation of MAPK cascade in acute quadriplegic myopathy.  Ann Neurol. 2004;  55 195-206
• 27 Dougherty J A. Risedronate for the prevention and treatment of corticosteroid-induced osteoporosis.  Ann Pharmacother. 2002;  36 512-516
• 28 Assouline-Dayan Y, Chang C, Greenspan A et al.. Pathogenesis and natural history of osteonecrosis.  Semin Arthritis Rheum. 2002;  32 94-124
• 29 Nielsen G L, Sorensen H T, Mellemkjoer L et al.. Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: A register-based cohort study.  Am J Med. 2001;  111 541-545
• 30 Metz L M, Sabuda D, Hilsden R J et al.. Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis.  Neurology. 1999;  53 2093-2096
• 31 Niv Y, Zlatkis L, Kosakov K. Cimetidine and encephalopathy.  Ann Intern Med. 1986;  105 977
• 32 Wade E E, Rebuck J A, Healey M A et al.. H(2) antagonist-induced thrombocytopenia: is this a real phenomenon?.  Intensive Care Med. 2002;  28 459-465
• 33 Rostom A, Dube C, Wells G et al.. Prevention of NSAID-induced gastroduodenal ulcers.  Cochrane Database Syst Rev. 2002;  CD002296
• 34 Weiner H L, Rezai A R, Cooper P R. Sigmoid diverticular perforation in neurosurgical patients receiving high-dose corticosteroids.  Neurosurgery. 1993;  33 40-43
• 35 Fadul C E, Lemann W, Thaler H T et al.. Perforation of the gastrointestinal tract in patients receiving steroids for neurological disease.  Neurology. 1988;  38 348-352
• 36 De Quervain D JF, Henke K, Aerni A et al.. Glucocorticoid-induced impairment of declarative memory retrieval is associated with reduced blood flow in the medial temporal lobe.  Eur J Neurosci. 2003;  17 1296-1302
• 37 Schiff D. Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features.  J Neurooncol. 1996;  27 235-240
• 38 Sirois F. Steroid psychosis: a review.  Gen Hosp Psychiatry. 2003;  25 27-33
• 39 Patten S B, Neutel C I. Corticosteroid-induced adverse psychiatric effects: incidence, diagnosis and management.  Drug Saf. 2000;  22 111-122
• 40 Oberndorfer S, Schmal T, Lahrmann H et al.. The frequency of seizures in patients with primary brain tumors or cerebral metastases. An evaluation from the Ludwig Boltzmann Institute of Neuro-Oncology and the Department of Neurology, Kaiser Franz Josef Hospital Vienna.  Wien Klin Wochenschr. 2002;  114 911-916
• 41 Vecht C J, Wagner G L, Wilms E B. Interactions between antiepileptic drugs and chemotherapeutic agents.  Neurology. 2003;  2 404-409
• 42 Glantz M J, Cole B F, Forsyth P A et al.. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors-report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 2000;  54 1886-1893
• 43 Mamon H J, Wen P Y, Burns A C et al.. Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy.  Epilepsia. 1999;  40 341-344
• 44 Temkin N R. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials.  Epilepsia. 2001;  42 515-524
• 45 Foy P M, Chadwick D W, Rajgopalan N et al.. Do prophylactic anticonvulsant drugs alter the pattern of seizures after craniotomy?.  J Neurol Neurosurg Psychiatry. 1992;  55 753-757
• 46 Lee A Y, Levine M N. Venous thromboembolism and cancer: risks and outcomes.  Circulation. 2003;  107 I17-I21
• 47 Chan A T, Atiemo A, Diran L K et al.. Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis.  J Thromb Thrombolysis. 1999;  8 139-142
• 48 Hamilton M G, Hull R D, Pineo G F. Venous thromboembolism in neurosurgery and neurology patients: a review.  Neurosurgery. 1994;  34 280-296
• 49 Sawaya R, Zuccarello M, Elkalliny M et al.. Postoperative venous thromboembolism and brain tumors: Part I. Clinical profile.  J Neurooncol. 1992;  14 119-125
• 50 Pinedo H M. Thrombosis, prevalence and new evidence on current perceptions of risk.  Cancer Treat Rev. 2003;  29(S2) 3-5
• 51 Goldhaber S Z, Dunn K, Gerhard-Herman M et al.. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis.  Chest. 2002;  122 1933-1937
• 52 Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis.  Arch Intern Med. 2000;  160 2327-2332
• 53 Turpie A G, Eriksson B I, Bauer K A et al.. New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies.  Chest. 2003;  124 371S-378S
• 54 Lee A Y, Levine M N, Baker R I et al.. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.  N Engl J Med. 2003;  349 146-153
• 55 Wells P S, Anderson D R, Rodger M et al.. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis.  N Engl J Med. 2003;  349 1227-1235
• 56 Macdonald R L, Amidei C, Lin G et al.. Safety of perioperative subcutaneous heparin for prophylaxis of venous thromboembolism in patients undergoing craniotomy.  Neurosurgery. 1999;  45 245-251
• 57 Constantini S, Kanner A, Friedman A et al.. Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: a prospective, randomized, double-blind study.  J Neurosurg. 2001;  94 918-921
• 58 Schiff D, DeAngelis L M. Therapy of venous thromboembolism in patients with brain metastases.  Cancer. 1994;  73 493-498
• 59 Levin J M, Schiff D, Loeffler J S et al.. Complications of therapy for venous thromboembolic disease in patients with brain tumors.  Neurology. 1993;  43 1111-1114
• 60 Gomes M P, Kaplan K L, Deitcher S R. Patients with inferior vena cava filters should receive chronic thromboprophylaxis.  Med Clin North Am. 2003;  87 1189-1203
• 61 Rubin H. Cancer cachexia: its correlations and causes.  Proc Natl Acad Sci U S A. 2003;  100 5384-5389
• 62 Chipkevitch E. Brain tumors and anorexia nervosa syndrome.  Brain Dev. 1994;  16 175-179
• 63 De Vile C J, Sufraz R, Lask B D et al.. Occult intracranial tumours masquerading as early onset anorexia nervosa.  BMJ. 1995;  311 1359-1360
• 64 Trummer M, Eustacchio S, Unger F et al.. Right hemispheric frontal lesions as a cause for anorexia nervosa report of three cases.  Acta Neurochir (Wien). 2002;  144 797-801
• 65 Takahashi T, Kazama Y, Shimizu H et al.. Brain metastases of malignant melanoma showing unbalanced whole arm chromosomal translocations der (8; 14) (q10; q10) and der (11; 15) (q10; q10) in a Japanese patient.  Intern Med. 2001;  40 956-960
• 66 Laviano A, Meguid M M, Rossi-Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies.  Lancet Oncol. 2003;  4 686-694
• 67 Comeau T B, Epstein J B, Migas C. Taste and smell dysfunction in patients receiving chemotherapy: a review of current knowledge.  Support Care Cancer. 2001;  9 575-580
• 68 Fehm-Wolfsdorf G, Scheible E, Zenz H et al.. Taste thresholds in man are differentially influenced by hydrocortisone and dexamethasone.  Psychoneuroendocrinology. 1989;  14 433-440
• 69 Ishimaru T, Miwa T, Nomura M et al.. Reversible hyposmia caused by intracranial tumour.  J Laryngol Otol. 1999;  113 750-753
• 70 Sagar S M, Thomas R J, Loverock L T et al.. Olfactory sensations produced by high-energy photon irradiation of the olfactory receptor mucosa in humans.  Int J Radiat Oncol Biol Phys. 1991;  20 771-776
• 71 Vissink A, Burlage F R, Spijkervet F K et al.. Prevention and treatment of the consequences of head and neck radiotherapy.  Crit Rev Oral Biol Med. 2003;  14 213-225
• 72 Vissink A, Jansma J, Spijkervet F K et al.. Oral sequelae of head and neck radiotherapy.  Crit Rev Oral Biol Med. 2003;  14 199-212
• 73 Minami M, Endo T, Hirafuji M et al.. Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity.  Pharmacol Ther. 2003;  99 149-165
• 74 Davis M P, Walsh D. Treatment of nausea and vomiting in advanced cancer.  Support Care Cancer. 2000;  8 444-452
• 75 Tremblay P B, Kaiser R, Sezer O et al.. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients.  J Clin Oncol. 2003;  21 2147-2155
• 76 Henzi I, Walder B, Tramer M R. Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review.  Anesth Analg. 2000;  90 186-194
• 77 Scalera G. Effects of conditioned food aversions on nutritional behavior in humans.  Nutr Neurosci. 2002;  5 159-188
• 78 Cerchietti L C, Navigante A H, Peluffo G D et al.. Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study.  J Pain Symptom Manage. 2004;  27 85-95
• 79 Sato K, Onuma E, Yocum R C et al.. Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody.  Semin Oncol. 2003;  30 167-173
• 80 Bruera E, Strasser F, Palmer J L et al.. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study.  J Clin Oncol. 2003;  21 129-134
• 81 Potter J, Hami F, Bryan T et al.. Symptoms in 400 patients referred to palliative care services: prevalence and patterns.  Palliat Med. 2003;  17 310-314
• 82 Klaschik E, Nauck F, Ostgathe C. Constipation-modern laxative therapy.  Support Care Cancer. 2003;  11 679-685
• 83 Smith S. Evidence-based management of constipation in the oncology patient.  Eur J Oncol Nurs. 2001;  5 18-25
• 84 Kurz A, Sessler D I. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.  Drugs. 2003;  63 649-671
• 85 Meyers C A, Smith J A, Bezjak A et al.. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.  J Clin Oncol. 2004;  22 157-165
• 86 Poppelreuter M, Weis J, Kulz A K et al.. Cognitive dysfunction and subjective complaints of cancer patients. a cross-sectional study in a cancer rehabilitation centre.  Eur J Cancer. 2004;  40 43-49
• 87 Sharpe M, Strong V, Allen K et al.. Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs.  Br J Cancer. 2004;  90 314-320
• 88 Jacobsen P B, Donovan K A, Weitzner M A. Distinguishing fatigue and depression in patients with cancer.  Semin Clin Neuropsychiatry. 2003;  8 229-240
• 89 Kelsen D P, Portenoy R K, Thaler H T et al.. Pain and depression in patients with newly diagnosed pancreas cancer.  J Clin Oncol. 1995;  13 748-755
• 90 Fisch M J, Loehrer P J, Kristeller J et al.. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group.  J Clin Oncol. 2003;  21 1937-1943
• 91 Atkinson A, Barsevick A, Cella D et al.. NCCN practice guidelines for cancer-related Fatigue.  Oncology. 2000;  14 151-161
• 92 Escalante C P. Treatment of cancer-related fatigue: an update.  Support Care Cancer. 2003;  11 79-83
• 93 Servaes P, van der Werf S, Prins J, Verhagen S, Bleijenberg G. Fatigue in disease-free cancer patients compared with fatigue in patients with chronic fatigue syndrome.  Support Care Cancer. 2001;  9 11-17
• 94 Pelletier G, Verhoef M J, Khatri N et al.. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues.  J Neurooncol. 2002;  57 41-49
• 95 Stasi R, Abriani L, Beccaglia P et al.. Cancer-related fatigue-evolving concepts in evaluation and treatment.  Cancer. 2003;  98 1786-1801
• 96 Cella D, Lai J S, Chang C H et al.. Fatigue in cancer patients compared with fatigue in the general United States population.  Cancer. 2002;  94 528-538
• 97 Crawford J, Cella D, Cleeland C S et al.. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.  Cancer. 2002;  95 888-895
• 98 Villa P, Bigini P, Mennini T et al.. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis.  J Exp Med. 2003;  198 971-975
• 99 Olsen N V. Central nervous system frontiers for the use of erythropoietin.  Clin Infect Dis. 2003;  37(S4) S323-S330
• 100 Forsyth P A, Posner J B. Headaches in patients with brain tumors: a study of 111 patients.  Neurology. 1993;  43 1678-1683
• 101 Jacox A, Carr D B, Payne R. New clinical-practice guidelines for the management of pain in patients with cancer.  N Engl J Med. 1994;  330 651-655
• 102 National Institutes of Health . Symptom management in cancer: pain, depression and fatigue: State-of-the-Science Conference Statement.  J Pain Palliat Care Pharmacother. 2003;  17 77-97
• 103 Tuma R, DeAngelis L M. Altered mental status in patients with cancer.  Arch Neurol. 2000;  57 1727-1731
• 104 McCusker J, Cole M, Abrahamowicz M et al.. Environmental risk factors for delirium in hospitalized older people.  J Am Geriatr Soc. 2001;  49 1327-1334
• 105 Ljubisavljevic V, Kelly B. Risk factors for development of delirium among oncology patients.  Gen Hosp Psychiatry. 2003;  25 345-352
• 106 Caraceni A, Nanni O, Maltoni M et al.. Impact of delirium on the short term prognosis of advanced cancer patients.  Cancer. 2000;  89 1145-1149
• 107 Caraceni A, Grassi L. DELIRIUM: Acute Confusional States in Palliative Medicine. Oxford; Oxford University Press 2003
• 108 Drislane F W. Nonconvulsive status epilepticus in patients with cancer.  Clin Neurol Neurosurg. 1994;  96 314-318
• 109 Towne A R, Waterhouse E J, Boggs J G et al.. Prevalence of nonconvulsive status epilepticus in comatose patients.  Neurology. 2000;  54 340-345
• 110 Primavera A, Audenino D, Cocito L. Ifosfamide encephalopathy and nonconvulsive status epilepticus.  Can J Neurol Sci. 2002;  29 180-183
• 111 Martinez-Rodriguez J E, Barriga F J, Santamaria J et al.. Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure.  Am J Med. 2001;  111 115-119
• 112 Vento S, Cainelli F. Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment.  Lancet Oncol. 2003;  4 595-604
• 113 Weimer L H. Medication-induced peripheral neuropathy.  Curr Neurol Neurosci Rep. 2003;  3 86-92
• 114 Thomas R J. Neurotoxicity of antibacterial therapy.  South Med J. 1994;  87 869-874
• 115 Cunha B A. Antibiotic side effects.  Med Clin North Am. 2001;  85 149-185